James M Luther

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. pmc Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury
    James M Luther
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
    Kidney Int 82:643-51. 2012
  2. pmc The renin-angiotensin-aldosterone system and glucose homeostasis
    JAMES MATTHEW LUTHER
    Vanderbilt University Medical Center, Nashville, TN 37232 2358, USA
    Trends Pharmacol Sci 32:734-9. 2011
  3. pmc Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets
    J M Luther
    Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, 2200 Pierce Ave, 560 RRB, Nashville, TN 37232 6602, USA
    Diabetologia 54:2152-63. 2011
  4. pmc Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta
    James M Luther
    Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232 6602, USA
    Endocrinology 150:2229-36. 2009
  5. ncbi request reprint Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism
    James M Luther
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 6602, USA
    Hypertension 48:1050-7. 2006
  6. pmc 17Beta-estradiol increases basal but not bradykinin-stimulated release of active t-PA in young postmenopausal women
    Mias Pretorius
    Department of Anesthesiology, Vanderbilt University School of Medicine, Nashville, Tenn, USA
    Hypertension 51:1190-6. 2008
  7. pmc Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt
    William B Lea
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Kidney Int 75:936-44. 2009
  8. pmc Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition
    Gary P Van Guilder
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 6602, USA
    Hypertension 51:454-9. 2008
  9. pmc Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis
    Annis M Marney
    Division of Diabetes, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232 6602, USA
    J Am Soc Nephrol 20:2246-52. 2009
  10. pmc Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis
    Jorge L Gamboa
    Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232 2372, USA
    J Am Soc Nephrol 23:334-42. 2012

Collaborators

Detail Information

Publications15

  1. pmc Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury
    James M Luther
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
    Kidney Int 82:643-51. 2012
    ..Thus, mineralocorticoid antagonism may have protective effects in the kidney beyond aldosterone synthase inhibition...
  2. pmc The renin-angiotensin-aldosterone system and glucose homeostasis
    JAMES MATTHEW LUTHER
    Vanderbilt University Medical Center, Nashville, TN 37232 2358, USA
    Trends Pharmacol Sci 32:734-9. 2011
    ..We review these findings in the context of pharmacological strategies interrupting the RAAS to highlight the potential application of these strategies to the prevention of diabetes progression...
  3. pmc Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets
    J M Luther
    Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, 2200 Pierce Ave, 560 RRB, Nashville, TN 37232 6602, USA
    Diabetologia 54:2152-63. 2011
    ..Aldosterone concentrations increase in obesity and predict the onset of diabetes. We investigated the effects of aldosterone on glucose homeostasis and insulin secretion in vivo and in vitro...
  4. pmc Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta
    James M Luther
    Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232 6602, USA
    Endocrinology 150:2229-36. 2009
    ..Endogenous aldosterone contributes to the acute stimulatory effect of Ang II on PAI-1 and ppET-1 mRNA expression in the heart; renin activity correlates with basal profibrotic gene expression in the kidney...
  5. ncbi request reprint Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism
    James M Luther
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 6602, USA
    Hypertension 48:1050-7. 2006
    ..In contrast, angiotensin II-induced oxidative stress, as measured by F(2)-isoprostanes, is mineralocorticoid receptor independent and may be pressor dependent...
  6. pmc 17Beta-estradiol increases basal but not bradykinin-stimulated release of active t-PA in young postmenopausal women
    Mias Pretorius
    Department of Anesthesiology, Vanderbilt University School of Medicine, Nashville, Tenn, USA
    Hypertension 51:1190-6. 2008
    ..17Beta-estradiol increases basal release of active t-PA in young postmenopausal women, consistent with enhanced vascular fibrinolytic function...
  7. pmc Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt
    William B Lea
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Kidney Int 75:936-44. 2009
    ..Our study shows that mineralocorticoid receptor antagonism and aldosterone synthase inhibition similarly decrease hypertrophy and interstitial fibrosis of the kidney and heart caused by angiotensin II and high salt...
  8. pmc Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition
    Gary P Van Guilder
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 6602, USA
    Hypertension 51:454-9. 2008
    ..In conclusion, the BDKRB2 BE1 polymorphism influences bradykinin type 2 receptor-mediated vasodilation during angiotensin-converting enzyme inhibition...
  9. pmc Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis
    Annis M Marney
    Division of Diabetes, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232 6602, USA
    J Am Soc Nephrol 20:2246-52. 2009
    ..Factors that increase the production of bradykinin or decrease its degradation may enhance the inflammatory response to hemodialysis...
  10. pmc Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis
    Jorge L Gamboa
    Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232 2372, USA
    J Am Soc Nephrol 23:334-42. 2012
    ..A prospective clinical trial is necessary to determine whether ACE inhibitors and ARBs also differ with respect to their effects on cardiovascular mortality in this population...
  11. ncbi request reprint Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans
    Laine J Murphey
    Department of Medicine and Pharmacology, Vanderbilt University, Nashville, TN 37232 6602, USA
    J Pharmacol Exp Ther 318:1287-92. 2006
    ..By inhibiting thrombin-induced platelet aggregation without causing vasodilation, bradykinin 1-5 may provide a model for small molecule substrate-selective thrombin inhibitors...
  12. pmc Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension
    Kimberly Gilbert
    Department of Medicine, Vanderbilt School of Medicine, Nashville, Tennessee, USA
    J Hypertens 31:820-9. 2013
    ..We tested the hypothesis that the effect of fenofibrate on blood pressure depends on salt sensitivity...
  13. ncbi request reprint Angiotensin-converting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men
    Mias Pretorius
    Veterans Affairs Medical Center, Department of Anesthesiology, Vanderbilt University School of Medicine, Nashville, TN, USA
    Arterioscler Thromb Vasc Biol 25:2435-40. 2005
    ..Angiotensin-converting enzyme inhibition (ACEI) increases vascular tissue plasminogen activator (t-PA) release through endogenous bradykinin (BK). We tested the hypothesis that gender influences the effect of ACEI on t-PA release...
  14. pmc Proteomic analysis of urine exosomes by multidimensional protein identification technology (MudPIT)
    Zhen Wang
    Department of Biochemistry, Vanderbilt University, Nashville, TN 37232, USA
    Proteomics 12:329-38. 2012
    ....
  15. pmc Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function
    James P Smith
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
    Antimicrob Agents Chemother 54:1146-51. 2010
    ....